

119TH CONGRESS
1ST SESSION

H. R. 6130

To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.

IN THE HOUSE OF REPRESENTATIVES

NOVEMBER 19, 2025

Mr. BUCHANAN (for himself and Mr. TONKO) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Alzheimer’s Screening
5 and Prevention Act of 2025” or the “ASAP Act”.

1 **SEC. 2. MEDICARE COVERAGE OF ALZHEIMER’S DISEASE**
 2 **AND RELATED DEMENTIAS EARLY DETEC-**
 3 **TION SCREENING TESTS.**

4 (a) COVERAGE.—Section 1861 of the Social Security
 5 Act (42 U.S.C. 1395x) is amended—

6 (1) in subsection (s)(2)—

7 (A) in subparagraph (JJ), by striking the
 8 semicolon at the end and inserting “; and”; and

9 (B) by adding at the end the following new
 10 subparagraph:

11 “(KK) Alzheimer’s disease and related demen-
 12 tias early detection screening tests (as defined in
 13 subsection (nnn));”; and

14 (2) by adding at the end the following new sub-
 15 section:

16 “(nnn) ALZHEIMER’S DISEASE AND RELATED DE-
 17 MENTIAS EARLY DETECTION SCREENING TESTS.—The
 18 term ‘Alzheimer’s disease and related dementias early de-
 19 tection screening test’ means a test furnished to an indi-
 20 vidual for the detection of the pre-symptomatic and early
 21 stage of Alzheimer’s disease or related dementias on or
 22 after January 1, 2028, that—

23 “(1) is cleared under section 510(k), classified
 24 under section 513(f)(2), or approved under section
 25 515 of the Federal Food, Drug, and Cosmetic Act;
 26 and

1 “(2) is—

2 “(A) a genomic sequencing blood or blood
3 product test; or

4 “(B) such other equivalent test, including
5 a single-analyte test, blood test analysis of cell-
6 free nucleic acids, multiplex panel test, whole
7 genome sequencing, protein expression, whole
8 exome, whole transcriptome, and medical imag-
9 ing (which are based on blood, blood products,
10 tissue, urine or other biospecimen), as the Sec-
11 retary determines appropriate in providing re-
12 sults comparable to those obtained with a test
13 described in subparagraph (A).”.

14 (b) PAYMENT.—Section 1833(h)(1)(A) of the Social
15 Security Act (42 U.S.C. 1395l(h)(1)(A)) is amended by
16 inserting “Alzheimer’s disease and related dementias early
17 detection screening tests under section 1861(nnn) and”
18 after “including”.

○